SAN CARLOS, Calif. and DALLAS, Aug. 27, 2025 /PRNewswire/ -- CAGE Bio Inc., a leader in advancing innovative therapies for targeted and localized treatment of immunological skin diseases, today announced it has entered into a collaboration with Mayo Clinic to develop novel therapeutics aimed at addressing unmet needs of patients with chronic graft-versus-host disease (GvHD).
Under this agreement, CAGE Bio and Mayo Clinic will focus on cutaneous GvHD, a debilitating condition that remains difficult to manage with potential adverse effects, impacting patients' quality of life*. The collaboration will combine Mayo Clinic's clinical expertise with CAGE Bio's proprietary ionic liquid technology to accelerate development of new treatment options.
"This engagement strengthens our innovative pipeline," said Dr. Nitin Joshi, Chief Executive Officer, CAGE Bio. "We are thrilled to collaborate with Mayo Clinic to jointly address significant unmet needs for patients with debilitating dermatological conditions. This collaboration highlights the value of CAGE Bio's ionic liquid technology for developing critical therapies for patients."
About CAGE Bio Inc.
CAGE Bio Inc. is a biotechnology company dedicated to developing innovative therapies for immune-mediated diseases using its proprietary ionic liquid technology platform. The company's pipeline includes clinical and preclinical assets targeting high incidence dermatological conditions.
Mayo Clinic has a financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education, and research.
* https://www.astctjournal.org/article/S2666-6367(21)00950-7/fulltext
www.CAGEBio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/cage-bio-announces-collaboration-to-advance-first-in-class-treatments-for-cutaneous-graft-versus-host-disease-302540347.html
SOURCE CAGE Bio Inc.